AngioDynamics, Inc. Q3 2026 Earnings Call Summary

3 weeks ago 10

Moby Intelligence

Thu, April 2, 2026 astatine 11:41 AM CDT 3 min read

Performance was driven by a deliberate displacement toward high-margin Med Tech markets, which present comprise 48% of full gross compared to 44% successful the anterior year.
Auryon achieved its 19th consecutive 4th of double-digit maturation by leveraging superior exertion to seizure marketplace stock and expanding successfully into the infirmary setting.
The Mechanical Thrombectomy portfolio grew 18% year-over-year, supported by a 'portfolio selling' attack that allows physicians to take betwixt AlphaVac and AngioVac based connected objective preference.
AlphaVac saw its largest sequential gross summation since launch, attributed to caller relationship wins done infirmary Value Analysis Committees (VAC) and accrued utilization successful existing accounts.
NanoKnife maturation was bolstered by the caller CPT Category 1 codification effectual January 1, which is facilitating broader marketplace entree and driving some superior income and probe utilization.
Management attributes the sustained show to a multi-year translation strategy involving manufacturing transitions and the divestiture of legacy, lower-growth businesses.

Full-year nett income guidance was raised to $313.5M–$315.5M, reflecting 15% to 17% expected maturation successful the Med Tech segment.
Adjusted EBITDA guidance was accrued to $10M–$12M, contempt anticipated structural gross borderline impacts and planned investments successful objective information improvement successful the 2nd half.
The institution expects to implicit the regulatory support process for the AlphaReturn Blood Management System by the archetypal 4th of calendar 2027.
Management anticipates generating important currency successful the 4th fiscal quarter, maintaining a trajectory toward affirmative currency travel contempt impermanent inventory builds.
Strategic absorption remains connected expanding NanoKnife's planetary footprint pursuing expanded European indications for multi-organ brushed insubstantial ablation.

Gross borderline decreased 110 ground points year-over-year owed to the timing of tariffs, inflationary pressures, and costs associated with the ongoing manufacturing modulation to Costa Rica.
The institution expects to incur $4M to $6M successful full tariff expenses for fiscal twelvemonth 2026, a headwind that was not contiguous successful the anterior twelvemonth period.
A proactive $3M to $5M currency concern successful inventory is planned for Q4 to mitigate imaginable proviso disruptions caused by scheduled attraction shutdowns astatine sterilization vendors.
The Board of Directors has initiated a ceremonial hunt for a caller CEO, with the existent enactment committed to a seamless modulation period.